| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.CCM.0000126120.49367.AC |
| P698 | PubMed publication ID | 15118522 |
| P2093 | author name string | David R Nelson | |
| William L Macias | |||
| P433 | issue | 5 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sepsis | Q183134 |
| protein C deficiency | Q1504570 | ||
| P304 | page(s) | S223-8 | |
| P577 | publication date | 2004-05-01 | |
| P1433 | published in | Critical Care Medicine | Q5186605 |
| P1476 | title | Severe protein C deficiency predicts early death in severe sepsis | |
| P478 | volume | 32 |
| Q83719164 | A neonate with complete thrombosis of the aorta |
| Q81019303 | A safety evaluation of drotrecogin alfa (activated) in hematopoietic stem cell transplant patients with severe sepsis: lessons in clinical research |
| Q33919261 | Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study |
| Q33373012 | Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency |
| Q64132601 | Advances in sepsis treatment |
| Q43764645 | Alterations in the hemostatic profiles of dogs with naturally occurring septic peritonitis |
| Q37724049 | Blood coagulation disorders in septic patients |
| Q37628848 | Changes in plasma levels of natural anticoagulants in disseminated intravascular coagulation: high prognostic value of antithrombin and protein C in patients with underlying sepsis or severe infection |
| Q40061916 | Current role of activated protein C therapy for severe sepsis and septic shock |
| Q43186023 | Distinct functions of activated protein C differentially attenuate acute kidney injury. |
| Q36607385 | Drotrecogin alfa (activated) in the treatment of severe sepsis |
| Q36981698 | Drotrecogin alpha (activated): the treatment for severe sepsis? |
| Q36295952 | Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity |
| Q92365798 | Endothelial Dysfunction Is Associated with Mortality and Severity of Coagulopathy in Patients with Sepsis and Disseminated Intravascular Coagulation |
| Q55715387 | Endpoint resuscitation-based prediction model for early mortality of severe sepsis and septic shock. |
| Q36919457 | Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center |
| Q34019901 | Extracellular histones are major mediators of death in sepsis |
| Q31141633 | Factors influencing early and late mortality in adults with invasive pneumococcal disease in Calgary, Canada: a prospective surveillance study |
| Q28578891 | FoxA2 involvement in suppression of protein C, an outcome predictor in experimental sepsis |
| Q48415621 | Human protein C zymogen concentrate in patients with severe sepsis and multiple organ failure after adult cardiac surgery. |
| Q24201123 | Human recombinant activated protein C for severe sepsis |
| Q24235181 | Human recombinant activated protein C for severe sepsis |
| Q24202128 | Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients |
| Q35196165 | Levels of protein C and soluble thrombomodulin in critically ill patients with acute kidney injury: a multicenter prospective observational study |
| Q38930881 | Low-grade endotoxemia and clotting activation in the early phase of pneumonia |
| Q36241437 | Meningococcal infections at the start of the 21st century. |
| Q90286414 | Mortality Risk Profiles for Sepsis: A Novel Longitudinal and Multivariable Approach |
| Q33754477 | New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study |
| Q83197798 | Plasma antithrombin III and protein C levels in early recognition of late-onset sepsis in newborns |
| Q80672463 | Plasma derived protein C in severe sepsis: report of two cases |
| Q84286596 | Positive culture for Klebsiella pneumoniae in relevant sputum samples as a predictor of rapidly fatal outcome in septic patients at medical intensive care units |
| Q36404178 | Potential vaccines and post-exposure treatments for filovirus infections |
| Q57159238 | Prediction of Early Death in Patients With Sepsis-Associated Coagulation Disorder Treated With Antithrombin Supplementation |
| Q36634005 | Prognostic utility and characterization of cell-free DNA in patients with severe sepsis |
| Q54548201 | Protein C -1641A/-1654C haplotype is associated with organ dysfunction and the fatal outcome of severe sepsis in Chinese Han population. |
| Q81725856 | Protein C as an early marker of severe septic complications in diffuse secondary peritonitis |
| Q46610474 | Protein C concentrate to restore physiological values in adult septic patients. |
| Q42905403 | Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome |
| Q37508524 | Protein C in critical illness |
| Q36749051 | Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated) |
| Q35561206 | Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated). |
| Q36424717 | Reversal of neutrophil-to-lymphocyte count ratio in early versus late death from septic shock |
| Q42588928 | Sepsis-associated disseminated intravascular coagulation and thromboembolic disease |
| Q33973581 | Several Cytokines and Protein C Levels with the Apache II Scoring System for Evaluation of Patients with Sepsis |
| Q37290652 | Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications |
| Q41449286 | Study of proinflammatory responses induced by Yersinia pestis in human monocytes using cDNA arrays |
| Q40283373 | Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies |
| Q24594601 | Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb |
| Q37082973 | The protein C pathway: implications for the design of the RESPOND study |
| Q90286346 | Thrombomodulin, Plasminogen Activator Inhibitor-1 and Protein C Levels, and Organ Dysfunction in Sepsis |
Search more.